Program
daridorexant
Also written as “Daridorexant”, “ACT-541468” and “Daridorexant 25 mg”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Sleep Apnea, Obstructive · Renal Insufficiency · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageDaridorexant: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Idorsia Pharmaceuticalsits history only | 311 open or running | phase 4since Oct 25, 2022 | Aug 14, 2015 | Nov 22, 2027phase 3 · NCT07843329 |
| Simcere Pharmaceutical Group | 20 open or running | phase 3since Aug 20, 2023 | Aug 20, 2023 | none ahead |
| Nxera Pharma Koreaits history only | 10 open or running | phase 3since Jun 11, 2025 | Jun 11, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Simcere Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2023First study: phase 3 study in Sleep Initiation and Maintenance DisordersFirst studyNCT06010693 · 206 enrolled · China
- Feb 17, 2024Phase 1 study in Healthy VolunteerNCT06326723 · 32 enrolled · China
TargetBeta
“Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist”ChEMBL 37, by rule
Studies
All 2 Simcere Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06326723Healthy Volunteer · China | 1 | Completed | Dec 24, 2023 | 32 |
| NCT06010693Sleep Initiation and Maintenance Disorders · China | 3 | Completed | Apr 12, 2024 | 206 |
How it is read
Names in the registry
- “Daridorexant”, 12 entries
- “ACT-541468”, 12 entries
- “Daridorexant 25 mg”, 5 entries
- “Daridorexant 50 mg”, 4 entries
- “Daridorexant 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Sleep Apnea, Obstructive, 2 studies
- Renal Insufficiency, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.